Cargando…

Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study

OBJECTIVE: Population‐based data on epilepsy syndromes and etiologies in early onset epilepsy are scarce. The use of next‐generation sequencing (NGS) has hitherto not been reported in this context. The aim of this study is to describe children with epilepsy onset before 2 years of age, and to explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Stödberg, Tommy, Tomson, Torbjörn, Barbaro, Michela, Stranneheim, Henrik, Anderlid, Britt‐Marie, Carlsson, Sofia, Åmark, Per, Wedell, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756847/
https://www.ncbi.nlm.nih.gov/pubmed/32964447
http://dx.doi.org/10.1111/epi.16701
_version_ 1783626631534870528
author Stödberg, Tommy
Tomson, Torbjörn
Barbaro, Michela
Stranneheim, Henrik
Anderlid, Britt‐Marie
Carlsson, Sofia
Åmark, Per
Wedell, Anna
author_facet Stödberg, Tommy
Tomson, Torbjörn
Barbaro, Michela
Stranneheim, Henrik
Anderlid, Britt‐Marie
Carlsson, Sofia
Åmark, Per
Wedell, Anna
author_sort Stödberg, Tommy
collection PubMed
description OBJECTIVE: Population‐based data on epilepsy syndromes and etiologies in early onset epilepsy are scarce. The use of next‐generation sequencing (NGS) has hitherto not been reported in this context. The aim of this study is to describe children with epilepsy onset before 2 years of age, and to explore to what degree whole exome and whole genome sequencing (WES/WGS) can help reveal a molecular genetic diagnosis. METHODS: Children presenting with a first unprovoked epileptic seizure before age 2 years and registered in the Stockholm Incidence Registry of Epilepsy (SIRE) between September 1, 2001 and December 31, 2006, were retrieved and their medical records up to age 7 years reviewed. Children who met the epilepsy criteria were included in the study cohort. WES/WGS was offered in cases of suspected genetic etiology regardless of whether a structural or metabolic diagnosis had been established. RESULTS: One hundred sixteen children were included, of which 88 had seizure onset during the first year of life and 28 during the second, corresponding to incidences of 139 and 42/100 000 person‐years, respectively. An epilepsy syndrome could be diagnosed in 54% of cases, corresponding to a birth prevalence of 1/1100. Structural etiology was revealed in 34% of cases, a genetic cause in 20%, and altogether etiology was known in 65% of children. The highest diagnostic yield was seen in magnetic resonance imaging (MRI) with 65% revealing an etiology. WES/WGS was performed in 26/116 cases (22%), with a diagnostic yield of 58%. SIGNIFICANCE: Epilepsy syndromes can be diagnosed and etiologies revealed in a majority of early onset cases. NGS can identify a molecular diagnosis in a substantial number of children, and should be included in the work‐up, especially in cases of epileptic encephalopathy, cerebral malformation, or metabolic disease without molecular diagnosis. A genetic diagnosis is essential to genetic counselling, prenatal diagnostics, and precision therapy.
format Online
Article
Text
id pubmed-7756847
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77568472020-12-28 Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study Stödberg, Tommy Tomson, Torbjörn Barbaro, Michela Stranneheim, Henrik Anderlid, Britt‐Marie Carlsson, Sofia Åmark, Per Wedell, Anna Epilepsia Full‐length Original Research OBJECTIVE: Population‐based data on epilepsy syndromes and etiologies in early onset epilepsy are scarce. The use of next‐generation sequencing (NGS) has hitherto not been reported in this context. The aim of this study is to describe children with epilepsy onset before 2 years of age, and to explore to what degree whole exome and whole genome sequencing (WES/WGS) can help reveal a molecular genetic diagnosis. METHODS: Children presenting with a first unprovoked epileptic seizure before age 2 years and registered in the Stockholm Incidence Registry of Epilepsy (SIRE) between September 1, 2001 and December 31, 2006, were retrieved and their medical records up to age 7 years reviewed. Children who met the epilepsy criteria were included in the study cohort. WES/WGS was offered in cases of suspected genetic etiology regardless of whether a structural or metabolic diagnosis had been established. RESULTS: One hundred sixteen children were included, of which 88 had seizure onset during the first year of life and 28 during the second, corresponding to incidences of 139 and 42/100 000 person‐years, respectively. An epilepsy syndrome could be diagnosed in 54% of cases, corresponding to a birth prevalence of 1/1100. Structural etiology was revealed in 34% of cases, a genetic cause in 20%, and altogether etiology was known in 65% of children. The highest diagnostic yield was seen in magnetic resonance imaging (MRI) with 65% revealing an etiology. WES/WGS was performed in 26/116 cases (22%), with a diagnostic yield of 58%. SIGNIFICANCE: Epilepsy syndromes can be diagnosed and etiologies revealed in a majority of early onset cases. NGS can identify a molecular diagnosis in a substantial number of children, and should be included in the work‐up, especially in cases of epileptic encephalopathy, cerebral malformation, or metabolic disease without molecular diagnosis. A genetic diagnosis is essential to genetic counselling, prenatal diagnostics, and precision therapy. John Wiley and Sons Inc. 2020-09-23 2020-11 /pmc/articles/PMC7756847/ /pubmed/32964447 http://dx.doi.org/10.1111/epi.16701 Text en © 2020 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Full‐length Original Research
Stödberg, Tommy
Tomson, Torbjörn
Barbaro, Michela
Stranneheim, Henrik
Anderlid, Britt‐Marie
Carlsson, Sofia
Åmark, Per
Wedell, Anna
Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study
title Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study
title_full Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study
title_fullStr Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study
title_full_unstemmed Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study
title_short Epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: A population‐based study
title_sort epilepsy syndromes, etiologies, and the use of next‐generation sequencing in epilepsy presenting in the first 2 years of life: a population‐based study
topic Full‐length Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756847/
https://www.ncbi.nlm.nih.gov/pubmed/32964447
http://dx.doi.org/10.1111/epi.16701
work_keys_str_mv AT stodbergtommy epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy
AT tomsontorbjorn epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy
AT barbaromichela epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy
AT stranneheimhenrik epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy
AT anderlidbrittmarie epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy
AT carlssonsofia epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy
AT amarkper epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy
AT wedellanna epilepsysyndromesetiologiesandtheuseofnextgenerationsequencinginepilepsypresentinginthefirst2yearsoflifeapopulationbasedstudy